Authorization

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs

The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week.

Humanigen, Inc. (NASDAQ:HGEN) was among the biggest decliners of the week after the company said the Food and Drug Administration refused to authorize its COVID-19 treatment for emergency use. Mersana Therapeutics, Inc. (MRSN) and Apellis Pharmaceuticals, Inc. (APLS) pulled back notably in reaction to clinical trial disappointments.

On the other hand, Surrozen, Inc. (NASDAQ: SRZN), which went public via a SPAC deal, advanced notably. Stifel initiated coverage of the stock with a Buy rating and $19 price target.

In a big-ticket M&A announcement, Kadmon Holdings, Inc. (NASDAQ:KDMN) struck a deal to be acquired by French pharma giant Sanofi (NASDAQ:SNY) for $1.9 billion in cash.

Here are the key catalytic events scheduled for the unfolding week:
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2021    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728293031